Skip to content
Actos, Glustin(pioglitazone)
Actoplus Met, Actos, Competact, Duetact, Incresync, Oseni, Tandemact (pioglitazone) is a small molecule pharmaceutical. Pioglitazone was first approved as Actos on 1999-07-15. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against peroxisome proliferator-activated receptor gamma. In addition, it is known to target transient receptor potential cation channel subfamily M member 3.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Actos (generic drugs available since 2012-10-26)
Combinations
Actoplus met, Duetact, Oseni (generic drugs available since 2012-10-26)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alogliptin benzoate
+
Pioglitazone hydrochloride
Tradename
Company
Number
Date
Products
OSENITakedaN-022426 RX2013-01-25
4 products, RLD
Show 1 discontinued
Glimepiride
+
Pioglitazone hydrochloride
Tradename
Company
Number
Date
Products
DUETACTTakedaN-021925 RX2006-07-28
2 products, RLD
Metformin hydrochloride
+
Pioglitazone hydrochloride
Tradename
Company
Number
Date
Products
ACTOPLUS METTakedaN-021842 RX2005-08-29
1 products, RLD, RS
Show 2 discontinued
Pioglitazone hydrochloride
Tradename
Company
Number
Date
Products
ACTOSTakedaN-021073 RX1999-07-15
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
actoplus metNew Drug Application2021-01-13
actosNew Drug Application2021-01-13
duetactNew Drug Application2021-01-13
oseniNew Drug Application2021-04-30
pioglitazoneANDA2023-06-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Alogliptin Benzoate / Pioglitazone Hydrochloride, Oseni, Takeda Pharms Usa
86370792029-06-04DP
78076892028-06-27DS, DPU-1337
81736632025-03-15U-1338
82885392025-03-15DP
Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa
93207142029-02-03DP
91016602027-01-22DP
Glimepiride / Pioglitazone Hydrochloride, Duetact, Takeda Pharms Usa
80711302028-06-08DP
77001282027-01-30DP
Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met Xr, Takeda Pharms Usa
77856272026-07-31DP
79599462026-07-31DP
84703682023-09-19DP
86689312023-09-19DP
90609412023-09-19DP
ATC Codes
A: Alimentary tract and metabolism drugs
A10: Drugs used in diabetes
A10B: Blood glucose lowering drugs, excl. insulins
A10BD: Combinations of oral blood glucose lowering drugs
A10BD05: Metformin and pioglitazone
A10BD06: Glimepiride and pioglitazone
A10BD09: Pioglitazone and alogliptin
A10BD12: Pioglitazone and sitagliptin
A10BG: Thiazolidinediones, blood glucose lowering drugs
A10BG03: Pioglitazone
HCPCS
No data
Clinical
Clinical Trials
457 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11731595833181
Diabetes mellitusD003920EFO_0000400E08-E1371511134
Insulin resistanceD007333EFO_000261428510528
Healthy volunteers/patients2411127
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.811411016
Metabolic syndromeD024821EFO_0000195E88.811316415
ObesityD009765EFO_0001073E66.9323614
Polycystic ovary syndromeD011085EFO_0000660E28.2414211
Coronary artery diseaseD003324I25.12247
Glucose intoleranceD018149HP_0000833R73.0321227
Show 41 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.91314
Rheumatoid arthritisD001172EFO_0000685M06.92114
Prostatic neoplasmsD011471C611214
Hiv-associated lipodystrophy syndromeD039682EFO_10013481113
Kidney transplantationD0160301113
Alzheimer diseaseD000544EFO_0000249F03123
DyslipidemiasD050171HP_0003119112
Risk reduction behaviorD04024211
Coronary restenosisD023903EFO_000422411
ProteinuriaD011507HP_0000093R8011
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034055
AlcoholismD000437EFO_0003829F10.1355
AsthmaD001249EFO_0000270J4544
Non-small-cell lung carcinomaD00228933
Oral leukoplakiaD007972K13.2133
Opioid-related disordersD009293EFO_0005611F11112
Squamous cell carcinomaD00229422
HepatitisD006505HP_0012115K75.922
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21122
HyperglycemiaD006943HP_0003074R73.91112
Show 36 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E84123
InfertilityD007246EFO_000054522
Castration-resistant prostatic neoplasmsD06412922
Peripheral arterial diseaseD058729EFO_000426511
Female infertilityD007247EFO_0008560N9711
PharmacokineticsD01059911
Drug interactionsD00434711
PneumoniaD011014EFO_0003106J1811
OverweightD050177E66.311
GastroparesisD018589EFO_1000948K31.8411
Show 14 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic nephropathiesD003928EFO_000040122
Urinary bladder neoplasmsD001749C6722
KetosisD007662HP_0002919R82.411
Diabetic ketoacidosisD016883EFO_100089711
SarcopeniaD055948EFO_1000653M62.8411
Peritoneal dialysisD01053011
HypertriglyceridemiaD015228EFO_000421111
HypogonadismD007006E23.011
Acquired immunodeficiency syndromeD000163EFO_0000765B2011
Laron syndromeD046150Orphanet_633E34.32111
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePIOGLITAZONE
INNpioglitazone
Description
Pioglitazone is a member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. It has a role as an insulin-sensitizing drug, an EC 2.7.1.33 (pantothenate kinase) inhibitor, a xenobiotic, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor, a ferroptosis inhibitor, a cardioprotective agent, a PPARgamma agonist, an antidepressant, a geroprotector and a hypoglycemic agent. It is a member of thiazolidinediones, an aromatic ether and a member of pyridines.
Classification
Small molecule
Drug classperoxisome proliferator activiating receptor (PPAR) agonists (thiazolidene derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Identifiers
PDB5Y2O
CAS-ID111025-46-8
RxCUI33738
ChEMBL IDCHEMBL595
ChEBI ID8228
PubChem CID4829
DrugBankDB01132
UNII IDX4OV71U42S (ChemIDplus, GSRS)
Target
Agency Approved
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Alternate
TRPM3
TRPM3
Organism
Homo sapiens
Gene name
TRPM3
Gene synonyms
KIAA1616, LTRPC3
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily M member 3
Protein synonyms
Long transient receptor potential channel 3, LTrpC-3, LTrpC3, Melastatin-2, MLSN2
Uniprot ID
Mouse ortholog
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 25,605 documents
View more details
Safety
Black-box Warning
Black-box warning for: Actoplus met, Actos, Duetact, Oseni, Pioglitazone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,353 adverse events reported
View more details